Overview

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Status:
RECRUITING

Trial end date:
2027-12-12

Target enrollment:

Participant gender:

Summary

The aim of this study is to evaluate the efficacy and safety of Tislelizumab with Fruquintinib, Metronidazole treatment in MSS/MSI-L advanced colorectal cancer patients with high abundance of Fusobacterium nucleatum in a single arm Phase II clinical.

Phase:

PHASE2

Details

Lead Sponsor:

Jing-yuan Fang, MD, Ph. D

Treatments:

HMPL-013
Metronidazole
tislelizumab